Researchers from the National University Singapore have developed an AI technology platform, the Quadratic Phenotypic Optimization Platform (QPOP), that could enable doctors to prescribe personalized treatment for patients with multiple myeloma.

Personalized treatment could be coming to myeloma patients in the near future.

Rashid et al. developed a computational platform to facilitate the discovery and optimization of drug combinations to treat multiple myeloma. The platform enables investigators to speed up drug combination design, using small experimental data sets to identify the most effective drug combinations targeted at individual patients. The authors validated the combination treatments and refined the drug dosages in mouse models and ex vivo patient samples.

Using small blood or bone marrow samples from patients, the platform is able to map the drug response that a set of drug combinations will have on a specific patient’s cancer cells. In this way, they can determine the best potential treatment combination and dosages.

The team is working towards translating this work into the clinic and plan to start a clinical study in 2019.

Reference:

Rashid et al. (2018) Optimizing Drug Combinations Against Multiple Myeloma Using a Quadratic Phenotypic Optimization Platform (QPOP). DOI: 10.1126/scitranslmed.aan0941

Myeloma News Will Artificial Intelligence Determine Personalized Treatments for Multiple Myeloma?